These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 28826596)
1. Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis. Alwaseem H; Frisch BJ; Fasan R Bioorg Med Chem; 2018 Apr; 26(7):1365-1373. PubMed ID: 28826596 [TBL] [Abstract][Full Text] [Related]
2. Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization. Kolev JN; O'Dwyer KM; Jordan CT; Fasan R ACS Chem Biol; 2014 Jan; 9(1):164-73. PubMed ID: 24206617 [TBL] [Abstract][Full Text] [Related]
3. Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs. Tyagi V; Alwaseem H; O'Dwyer KM; Ponder J; Li QY; Jordan CT; Fasan R Bioorg Med Chem; 2016 Sep; 24(17):3876-3886. PubMed ID: 27396927 [TBL] [Abstract][Full Text] [Related]
4. Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD). Penthala NR; Balasubramaniam M; Dachavaram SS; Morris EJ; Bhat-Nakshatri P; Ponder J; Jordan CT; Nakshatri H; Crooks PA Eur J Med Chem; 2021 Nov; 224():113675. PubMed ID: 34229108 [TBL] [Abstract][Full Text] [Related]
5. Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. Bommagani S; Ponder J; Penthala NR; Janganati V; Jordan CT; Borrelli MJ; Crooks PA Eur J Med Chem; 2017 Aug; 136():393-405. PubMed ID: 28525840 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and in vivo anticancer activity of novel parthenolide and micheliolide derivatives as NF-κB and STAT3 inhibitors. Zeng B; Cheng Y; Zheng K; Liu S; Shen L; Hu J; Li Y; Pan X Bioorg Chem; 2021 Jun; 111():104973. PubMed ID: 34004586 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues. Kempema AM; Widen JC; Hexum JK; Andrews TE; Wang D; Rathe SK; Meece FA; Noble KE; Sachs Z; Largaespada DA; Harki DA Bioorg Med Chem; 2015 Aug; 23(15):4737-4745. PubMed ID: 26088334 [TBL] [Abstract][Full Text] [Related]
8. Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents. Liu X; Wang X Chin J Nat Med; 2022 Nov; 20(11):814-829. PubMed ID: 36427916 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive Structure-Activity Profiling of Micheliolide and its Targeted Proteome in Leukemia Cells via Probe-Guided Late-Stage C-H Functionalization. Alwaseem H; Giovani S; Crotti M; Welle K; Jordan CT; Ghaemmaghami S; Fasan R ACS Cent Sci; 2021 May; 7(5):841-857. PubMed ID: 34079900 [TBL] [Abstract][Full Text] [Related]
11. Antileukemic activity of aminoparthenolide analogs. Nasim S; Crooks PA Bioorg Med Chem Lett; 2008 Jul; 18(14):3870-3. PubMed ID: 18590961 [TBL] [Abstract][Full Text] [Related]
12. Anti-cancer activity of carbamate derivatives of melampomagnolide B. Janganati V; Penthala NR; Madadi NR; Chen Z; Crooks PA Bioorg Med Chem Lett; 2014 Aug; 24(15):3499-502. PubMed ID: 24928404 [TBL] [Abstract][Full Text] [Related]
13. Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells. Yun BR; Lee MJ; Kim JH; Kim IH; Yu GR; Kim DG Exp Mol Med; 2010 Nov; 42(11):787-97. PubMed ID: 20938215 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-acute myeloid leukemia activity of C-14 modified parthenolide derivatives. Yang Z; Kuang B; Kang N; Ding Y; Ge W; Lian L; Gao Y; Wei Y; Chen Y; Zhang Q Eur J Med Chem; 2017 Feb; 127():296-304. PubMed ID: 28068601 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of dual-action parthenolide prodrugs as potent anticancer agents. Taleghani A; Nasseri MA; Iranshahi M Bioorg Chem; 2017 Apr; 71():128-134. PubMed ID: 28215600 [TBL] [Abstract][Full Text] [Related]
16. Parthenolide: from plant shoots to cancer roots. Ghantous A; Sinjab A; Herceg Z; Darwiche N Drug Discov Today; 2013 Sep; 18(17-18):894-905. PubMed ID: 23688583 [TBL] [Abstract][Full Text] [Related]
17. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth. Li X; Kong L; Yang Q; Duan A; Ju X; Cai B; Chen L; An T; Li Y J Biol Chem; 2020 Mar; 295(11):3576-3589. PubMed ID: 32029476 [TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma. Ding Y; Li S; Ge W; Liu Z; Zhang X; Wang M; Chen T; Chen Y; Zhang Q Eur J Med Chem; 2019 Dec; 183():111706. PubMed ID: 31553932 [TBL] [Abstract][Full Text] [Related]
19. Fluorinated amino-derivatives of the sesquiterpene lactone, parthenolide, as (19)f NMR probes in deuterium-free environments. Woods JR; Mo H; Bieberich AA; Alavanja T; Colby DA J Med Chem; 2011 Nov; 54(22):7934-41. PubMed ID: 22029741 [TBL] [Abstract][Full Text] [Related]
20. Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. Albayati ZAF; Janganati V; Chen Z; Ponder J; Breen PJ; Jordan CT; Crooks PA Bioorg Med Chem; 2017 Feb; 25(3):1235-1241. PubMed ID: 28049618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]